Y Intercept Hong Kong Ltd Acquires 52,414 Shares of Viridian Therapeutics, Inc. $VRDN

Y Intercept Hong Kong Ltd raised its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 430.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 64,594 shares of the company’s stock after buying an additional 52,414 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Viridian Therapeutics were worth $1,394,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Farther Finance Advisors LLC raised its position in shares of Viridian Therapeutics by 332.1% in the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after purchasing an additional 1,491 shares during the period. Sei Investments Co. bought a new stake in shares of Viridian Therapeutics during the 2nd quarter worth about $147,000. Creative Planning acquired a new position in Viridian Therapeutics in the 2nd quarter valued at about $179,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Viridian Therapeutics in the 2nd quarter valued at about $180,000. Finally, Envestnet Asset Management Inc. bought a new position in Viridian Therapeutics in the 2nd quarter valued at about $187,000.

Viridian Therapeutics Stock Down 1.7%

Shares of NASDAQ VRDN opened at $33.00 on Friday. The stock has a market capitalization of $3.15 billion, a P/E ratio of -10.93 and a beta of 0.90. The stock’s fifty day moving average is $32.11 and its 200 day moving average is $24.71. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $34.29. The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.28 and a current ratio of 11.28.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.48. The business had revenue of $70.57 million during the quarter, compared to analysts’ expectations of $16.21 million. Viridian Therapeutics had a negative net margin of 426.58% and a negative return on equity of 78.50%. The company’s quarterly revenue was up 81993.0% compared to the same quarter last year. Sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Insider Buying and Selling at Viridian Therapeutics

In related news, insider Jennifer Tousignant sold 2,272 shares of the stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total transaction of $70,795.52. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on VRDN. Royal Bank Of Canada boosted their price objective on Viridian Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Wednesday, January 21st. Truist Financial reduced their price target on Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. UBS Group started coverage on Viridian Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Evercore ISI reissued an “outperform” rating and set a $44.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Viridian Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $42.43.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.